The Cortex Cast is a water-proof, light weight arm cast said to provide customisable support to the body as an alternative to traditional plaster casts.
Jake Evill, a recent university graduate in New Zealand, is the creator behind a revolutionary 3D printed arm cast whose provocative design is beyond eye-catching but lightweight, water-proof and inexpensive.
Called the Cortex Cast, his unique design uses a honeycomb structure similar to natural bone tissue to durably support and protect the body as an alternative to the bulk, weight and suffocation from ordinary plaster casts, according to Evill.
More importantly, he says, each cast is entirely custom-made to each user’s body to ensure the greatest support in areas most needed for healing, while comfortably following the contours of the hand and arm.
The unique prototype is the result of Evill’s senior design project at Victoria University in Wellington. Using a home-made 3-D scanner, crafted from an adapted X-Box Kinect system, he was able to produce a clear scan of his own arm, one recently broken and confined to a cast inspiring his design.
Today the Cortex Cast has peaked interest from orthopaedic surgeons in Europe and the U.S.
Currently, there is no cure for type 2 diabetes. However, researchers say they’re onto a potential treatment that can restore normal insulin activity, normalising blood sugar levels with just one injection.
In mice with diet-induced diabetes – the equivalent of type 2 diabetes in humans – a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery could lead to a new generation of safer, more effective diabetes drugs.
The team found that sustained treatment with the protein doesn’t merely keep blood sugar under control, but also reverses insulin insensitivity – the underlying physiological cause of diabetes. Equally exciting, the newly developed treatment did not cause any detrimental side effects or cause glucose levels to drop precipitously, unlike most current diabetes treatments.
Those who visited us at our stand at the Lab Innovations Exhibition back in November last year may remember the excitement surrounding our BATAK wall challenge.
The very clear winner of the challenge was Frank Barker, with an exceptional score of 96 points!
Frank received two tickets to the Formula 1 Santander British Grand Prix, which was held on Sunday 6th of July.
And here he is! Enjoying the sunshine on the track with his Dad.
Congratulations on winning the tickets Frank, we hope you had an amazing day!
Researchers have identified a set of proteins present in the blood which can be used to predict the onset of Alzheimer’s with almost 90% accuracy. The team believes that this discovery could not only be used to improve clinical trials for Alzheimer’s drugs, but it may also eventually lead to a blood test for Alzheimer’s.
Alzheimer’s is the most common form of dementia, usually affecting people over the age of 65. Currently, 44 million people worldwide have dementia; this is predicted to rise to 135 million in 2050. Unfortunately, there are no effective drug treatments for Alzheimer’s.
Researchers wanted to find a way to identify patients presenting mild cognitive impairment that will likely develop Alzheimer’s in order to enroll them into clinical trials. It is hoped that this will speed up the discovery of drugs that can prevent or treat the condition.
For the study, researchers from Oxford University and King’s College London analyzed the blood of over 1,000 individuals; 476 had Alzheimer’s, 220 had mild cognitive impairment and 452 were elderly controls without dementia. The team was interested in the levels of 26 proteins that were previously found to be associated with Alzheimer’s.
They discovered that of these proteins, 10 were strongly associated with disease severity and progression. Furthermore, these proteins in combination could be used to predict whether individuals with mild cognitive decline would develop Alzheimer’s within one year with a high level of accuracy (87%).
“A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease,” said lead researcher Simon Lovestone in a news-release. “The next step will be to validate our findings in further sample sets, to see if we can improve accuracy and reduce the risk of misdiagnosis, and to develop a reliable test suitable to be used by doctors.”
Image credit: Cardinal Senior Care
A healthy organ suffers tissue death after removal from the body and can last around 12 hours prior to transplantation. It is using a new ‘supercooling’ technique, which US researchers claim they can preserve organs for DAYS after they are removed from the body.
Supercooling combines chilling the organ and pumping nutrients and oxygen through its blood vessels. This new technique could extend the amount of time to a couple of days by supercooling the organ without freezing it.
The researchers took rat livers and treated them with oxygen and cooled chemicals that act as an anti-freeze, and slowly brought the livers down to 4 °C (39 °F) without completely freezing them. They were then stored at -6 °C (21.2 °F) for three days. The livers were slowly rewarmed and transplanted into recipient rats. The rats that received livers that had been supercooled were all alive three months after the transplant. A control group of rats were given livers that had been stored for three days using conventional methods, though none of those animals lived for three months after the surgery.
Though the technique was done with livers, the researchers believe this could eventually be done using any transplant organ. If this technique eliminates the strict 12 hour available window, there could be up to 5,000 additional organs available for transplant every year.